Lipoprotein (a), Where are we now?

Aims & Scope:

Lipoprotein (a) [Lp(a)] has been troubling the scientific community for several years. Though > 50 years have passed since its detection, no drug that specifically lowers high Lp(a) plasma levels has been discovered yet.

A few years ago (in 2010), guidelines for the management of high Lp(a) levels were published, recommending not only the use of hypolipidemic drugs but also low density lipoprotein (LDL) apheresis.

In view of the upcoming interest on Lp(a) management [i.e. antisense therapy targeting apolipoprotein (a)] and PSCK-9 inhibitors, we would like to publish a hot mini topic issue entitled: “Lipoprotein (a), Where are we now?”

Keywords: Lipoprotein (a).

Subtopics:

1. Lipoprotein (a) evolution: possible benefits and harm; Genetic and non-genetic factors influencing its plasma level.
2. Lipoprotein (a) and cardiovascular risk
3. Lipoprotein (a) management I: lifestyle and hormones
4. Lipoprotein (a) management II: pharmacological and apheretic treatment